The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Majid MomenyFatemeh EsmaeiliSepideh HamzehlouHassan YousefiSepehr JavadikoosheshVasimeh VahdatiradZivar AlishahiSeyedeh H MousavipakDavood BashashAhmad R DehpourSeyyed M TavangarJavad Tavakkoly-BazzazPeiman HaddadFarzaneh KordbachehKamran AlimoghaddamArdeshir GhavamzadehSeyed H GhaffariPublished in: Cellular oncology (Dordrecht) (2019)
Our findings indicate that dacomitinib-mediated blockade of the ERBB receptors yields advantages over single-targeted ERBB inhibition and provide a rationale for further investigation of the therapeutic potential of dacomitinib in the treatment of ERBB-driven PDAC.